The trial evaluated the safety, pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme’s Enhanze technology in hereditary angioedema (HAE).
Enhanze technology is a drug delivery platform using Halozyme’s recombinant human hyaluronidase enzyme.
ViroPharma chief scientific officer Colin Broom said the preliminary data suggest that rHuPH20 enhances the delivery and absorption of Cinryze, and increases systemic exposure to C1 inhibitor relative to subcutaneous Cinryze administered alone.